Teenager Becomes First in World to Achieve remission from leukemia with Groundbreaking gene-Editing Therapy
A 16-year-old from Leicester, England, has become the first person globally to be declared cancer-free after undergoing a revolutionary treatment that utilizes gene editing to fight aggressive forms of blood cancer, especially those for whom conventional treatments have failed.
Alyssa was diagnosed with T-cell leukemia in May 2021, following months of symptoms initially dismissed as common colds and fatigue. Despite undergoing chemotherapy and a bone marrow transplant, her cancer proved resistant, leading doctors to consider the experimental BE-CAR7 therapy.
“palliative care felt like the only option left,” Alyssa recounted, “until the research prospect was proposed.” She received the therapy in 2022, and within a short period, her leukemia became undetectable. Now, three years later, she has been discharged for long-term follow-up and is pursuing her dream of becoming a research scientist.
The innovative treatment,developed by scientists at Great Ormond street Hospital (Gosh) and University College London (UCL),centers around editing healthy immune cells to target and destroy cancer cells.Traditional CAR T-cell therapy involves modifying a patient’s own T cells to recognize and attack cancer. However, this approach is complex in leukemia cases originating from abnormal T cells.
BE-CAR7 utilizes a novel technique called base editing, which allows researchers to precisely alter the DNA code within living cells. Healthy T cells from a donor are “tweaked” to disarm them, preventing attacks on normal cells, and then equipped to rapidly find and eliminate all T-cells in the body, including cancerous ones. If the leukemia is eradicated within four weeks, the patient’s immune system is then rebuilt through a bone marrow transplant.
A clinical trial involving nine children and four adults with T-cell acute lymphoblastic leukemia (T-ALL) demonstrated the treatment’s efficacy. Remarkably, over two-thirds of the participants are now cancer-free, and 82% achieved deep remission, allowing them to proceed with stem cell transplants without evidence of disease. While some patients experienced side effects like low blood count and rashes, researchers deemed them manageable.
“We previously showed promising results using precision genome editing for children with aggressive blood cancer, and this larger number of patients confirms the impact of this type of treatment,” explained Waseem Qasim, a professor of cell and gene therapy at UCL and honorary consultant immunologist at Gosh. “We’ve shown that universal or ‘off-the-shelf’ base-edited CAR T-cells can seek and destroy very resistant cases of CD7+ leukemia.”
dr. Rob Chiesa, a bone marrow transplant consultant at Gosh and study investigator, emphasized the meaning of this breakthrough for patients with limited options. “Although most children with T-cell leukemia will respond well to standard treatments, around 20 percent may not. It’s these patients who desperately need better options, and this research provides hope for a better prognosis for everyone diagnosed with this rare but aggressive form of blood cancer.”
Alyssa, pictured with her family, embodies this hope. “I chose to take part in the research as I felt that, even if it didn’t work for me, it could help others,” she said. “Years later, we know it worked, and I’m doing really well. I’ve done all those things that you’re supposed to do when you’re a teenager – I’ve gone sailing, spent time away from home doing my Duke of Edinburgh Award, but even just going to school is something I dreamed of when I was ill. I’m not taking anything for granted. Next on my list is learning to drive, but my ultimate goal is to become a research scientist and be part of the next big discovery that can help people like me.”
The findings from this groundbreaking clinical trial have been published in the New England Journal of Medicine and were presented at the 67th American Society of Hematology Annual Meeting in florida. This research marks a significant step forward in the fight against leukemia and offers a beacon of hope for patients and families facing this devastating disease.
